SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28736 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Benedict Vanlerberghe und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Laboratory of Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Onderzoeksraad, KU Leuven.
Abstract (Originalsprache)
Rates and modulators of SARS‐CoV‐2 vaccine nonresponse and breakthrough infections remain unclear in serially vaccinated transplant recipients. In a prospective, mono‐centric, observational study, 1878 adult solid organ and hematopoietic cell transplant recipients, with prior SARS‐CoV‐2 vaccination, were included between March 2021 and February 2022. SARS‐CoV‐2 anti‐spike IgG antibodies were measured at inclusion and details on SARS‐CoV‐2 vaccine doses and infection were collected. No life‐threatening adverse events were reported after a total of 4039 vaccine doses. In transplant recipients without prior SARS‐CoV‐2 infection ( n = 1636), antibody response rates ranged widely, from 47% in lung transplant to 90% in liver transplant and 91% in hematopoietic cell transplant recipients after third vaccine dose. Antibody positivity rate and levels increased after each vaccine dose in all types of transplant recipients. In multivariable analysis, older age, chronic kidney disease and daily dose of mycophenolate and corticosteroids were negatively associated with antibody response rate. Overall rate of breakthrough infections was 25.2% and mainly (90.2%) occurred after third and fourth vaccine dose. Lung transplant recipients had the highest rates of severe breakthrough infection (10.5%) and death (2.5%). In multivariable analysis, older age, daily dose of mycophenolate and corticosteroids were associated with severe breakthrough infection. Transplant recipients with infection before first vaccine dose ( n = 160) had higher antibody response rates and levels after each vaccine dose, and a significantly lower overall rate of breakthrough infections compared to those without prior infection. Antibody response after SARS‐CoV‐2 vaccination and rate of severe breakthrough infections vary largely between different transplant types and are modulated by specific risk factors. The observed heterogeneity supports a tailored approach against COVID‐19 in transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Laboratory of Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Public Health and Critical Care, I-BioStat, KU Leuven & University Hasselt, Leuven & Hasselt, Belgium.
- Department of Laboratory Medicine, Department of Microbiology, Immunology and Transplantation, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Laboratory of Cardiovascular Sciences, Department of Cardiac Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Thoracic Surgery, University Hospitals Leuven, CHROMETA, KU Leuven, Leuven, Belgium.
- Laboratory of Microbiology, Immunology and Transplantation, Department of Abdominal Transplant Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Förderung
- Onderzoeksraad, KU Leuven
Zitieren
APA
Vanlerberghe, B., Vrij, C., Bogaerts, K., Vermeersch, P., Lagrou, K., Molenberghs, G., Rega, F., Ceulemans, L. J., van Raemdonck, D., Jochmans, I., Monbaliu, D., Pirenne, J., Vanuytsel, T., Gillard, P., Schoemans, H., Cleemput, J. V., Kuypers, D., Vos, R., Nevens, F., & Verbeek, J. (2023). SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients. Journal of Medical Virology. https://doi.org/10.1002/jmv.28736
Vancouver
Vanlerberghe B, Vrij C, Bogaerts K, Vermeersch P, Lagrou K, Molenberghs G, et al. SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients. Journal of Medical Virology. 2023. doi:10.1002/jmv.28736
BibTeX
@article{Vanlerberghe2023,
author = {Vanlerberghe, Benedict and Vrij, Casper and Bogaerts, Kris and Vermeersch, Pieter and Lagrou, Katrien and Molenberghs, Geert and Rega, Filip and Ceulemans, Laurens J and van Raemdonck, Dirk and Jochmans, Ina and Monbaliu, Diethard and Pirenne, Jacques and Vanuytsel, Tim and Gillard, Pieter and Schoemans, Hélène and Cleemput, Johan Van and Kuypers, Dirk and Vos, Robin and Nevens, Frederik and Verbeek, Jef},
title = {SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28736}
}
EUVIMED